Tech Company Inital Public Offerings
Fulcrum Therapeutics IPO
On 7/17/2019, Fulcrum Therapeutics went public.
Transaction Overview
Company Name
Announced On
7/17/2019
Transaction Type
IPO
Amount
$72,000,000
Proceeds Purpose
Per the firm's latest filing, it plans to use the net proceeds from the IPO combined with its existing cash as follows: approximately $45.0 million to advance losmapimod for FSHD; approximately $15.0 million to advance our hemoglobinopathies program: approximately $30.0 million to fund our ongoing product engine and discovery efforts; and the remainder for working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
26 Landsdowne St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Fulcrum Therapeutics (Nasdaq: FULC) is here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. Above all we are champions for our patients. Trust, Respect, Compassion and Integrity define who we are.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Gould
Chief Scientific Officer
Owen Wallace
Vice President
Diego Cadavid
Vice President
Lucienne Ronco
VP - Finance
Peter Thomson
VP - Human Resources
Kim Hazen
Browse more venture capital transactions:
Prev: 7/17/2019: Patreon venture capital transaction
Next: 7/17/2019: SubStack venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs